Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday.
The study will evaluate the vaccine for safety, tolerability and the level of immune response, as both a primary series and a booster dose, in up to 1,420 healthy adults ages 18 to 55.
The study is broken up into three groups:Participants in the first cohort have received two doses of the current Pfizer Covid-19 vaccine at least 90 to 180 days before the study. They will receive one or two doses of the Omicron-specific vaccine.
